In addition, it also suggested that the risk of AKI is higher with combination therapy (anti-CTLA-4 plus anti-PD-1) than with ICIs alone, and ICIs are time-dependent and dose-dependent, that is, the higher the target concentration, the more side effects. The gene discussed is CTLA4; the disease is acute kidney injury.